Intellia Therapeutics Inc (NTLA) concluded trading on Wednesday at a closing price of $10.73, with 7.23 million shares of worth about $77.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.36% during that period and on July 02, 2025 the price saw a gain of about 8.60%. Currently the company’s common shares owned by public are about 103.54M shares, out of which, 97.42M shares are available for trading.
Stock saw a price change of 12.24% in past 5 days and over the past one month there was a price change of 49.86%. Year-to-date (YTD), NTLA shares are showing a performance of -52.06% which decreased to -7.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.90 but also hit the highest price of $28.18 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 4.46 million. The stock is currently trading 19.24% above its 20-day simple moving average (SMA20), while that difference is up 24.39% for SMA50 and it goes to -10.35% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 103.54M outstanding shares and institutions hold larger chunk of about 92.29% of that.
The stock has a current market capitalization of $1.11B and its 3Y-monthly beta is at 2.29. It has posted earnings per share of -$5.23 in the same period. It has Quick Ratio of 4.90 while making debt-to-equity ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 7.63% while standing at 7.75% over the month.
Stock’s fiscal year EPS is expected to rise by 20.55% while it is estimated to increase by 7.74% in next year. EPS is likely to grow at an annualized rate of 31.48% for next 5-years, compared to annual growth of -20.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on April 21, 2025 offering an Outperform rating for the stock and assigned a target price of $21 to it. Coverage by H.C. Wainwright stated Intellia Therapeutics Inc (NTLA) stock as a Buy in their note to investors on March 05, 2025, suggesting a price target of $30 for the stock. On February 28, 2025, JP Morgan Downgrade their recommendations, while on February 28, 2025, Goldman Downgrade their ratings for the stock with a price target of $9. Stock get an Equal-weight rating from Morgan Stanley on January 27, 2025.
